Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, London, UK.
Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, London, UK.
Lancet Neurol. 2010 Dec;9(12):1182-1199. doi: 10.1016/S1474-4422(10)70249-0.
Management of symptoms in multiple sclerosis (MS) has received little attention compared with disease-modifying treatments. However, the effect of these symptoms on quality of life can be profound. Clinical trials of pharmacological drugs to treat symptoms of MS have often been underpowered and have used inappropriate measures of outcome. Many currently used symptomatic drugs were introduced decades ago, when study quality was considerably below current standards. Therefore, the evidence base on which to make clinical decisions is less than adequate. Interest in pharmacological treatment of symptoms in MS has increased in recent years, and several large randomised controlled trials have been reported. Pharmacological strategies are a core component of the treatment of these symptoms, but it is imperative to remember that a multidisciplinary rehabilitation approach is needed for effective management.
与疾病修正治疗相比，多发性硬化症（MS）症状的管理受到的关注较少。然而，这些症状对生活质量的影响可能是深远的。针对多发性硬化症症状的药物治疗的临床试验通常缺乏效力，并且使用了不适当的结果衡量标准。许多目前使用的对症药物是几十年前引入的，当时研究质量远低于当前标准。因此，用于做出临床决策的证据基础不足。近年来，人们对多发性硬化症症状的药物治疗产生了兴趣，并且已经报告了几项大型随机对照试验。药物治疗策略是治疗这些症状的核心组成部分，但必须记住，需要多学科康复方法来进行有效的管理。
